Rigel Plans Presentations At The Upcoming 2024 ASCO Annual Meeting And EHA2024 Hybrid Congress
Portfolio Pulse from Benzinga Newsdesk
Rigel Pharmaceuticals plans to present final five-year results from its Phase 2 trial of REZLIDHIA (olutasidenib) in R/R mIDH1 AML patients at the 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress. The results reinforce the efficacy of REZLIDHIA in heavily pretreated patients.
May 23, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rigel Pharmaceuticals will present final five-year results from its Phase 2 trial of REZLIDHIA (olutasidenib) at the 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress. The results reinforce the efficacy of REZLIDHIA in heavily pretreated R/R mIDH1 AML patients.
The presentation of positive final five-year results from the Phase 2 trial of REZLIDHIA at major medical conferences is likely to boost investor confidence in Rigel Pharmaceuticals. The efficacy in heavily pretreated patients suggests strong potential for the drug, which could positively impact RIGL's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100